Why the study?
Does trimetazidine improve left ventricular function and myocardial energy metabolism (PCr/ATP ratio) in patients with heart failure?
Population
12 patients with heart failure
Comparison
Trimetazidine 20 mg t.i.d. for 90 days vs Placebo for 90 days (cross-over design)
Design
RCT, randomized in a cross-over study, double-blind
Follow-up
two periods of 90 days
Authors
Loading...
Supports adjunctive trimetazidine in HF; extends metabolic modulation evidence and warrants outcome trials.
Does trimetazidine improve left ventricular function and myocardial energy metabolism (PCr/ATP ratio) in patients with heart failure?
Trimetazidine improves myocardial energy metabolism (PCr/ATP ratio), functional class, and ejection fraction in patients with heart failure.
Fragasso et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: